China's Next-Generation Industrial Policy: Biotech Implications

How expanding state intervention is redrawing the biotech landscape

A decade after Made in China 2025 (MIC25), Beijing is entering a new phase of industrial policy that is broader, more systemic, and more consequential for global markets than before. While much of the attention has focused on semiconductors, artificial intelligence, and new energy vehicles, biotechnology occupies an increasingly important position in China's industrial strategy. A recent comprehensive assessment by Rhodium Group, commissioned by the U.S. Chamber of Commerce, provides the most detailed picture yet of how China's next-generation industrial policy is evolving. The report makes clear that state intervention now touches virtually every major sector and supply chain layer. For the life sciences and biotechnology industry, these dynamics are accelerating China's domestic build-out while intensifying competitive pressure on foreign companies and reshaping global value chains.

Executive Summary

China's industrial strategy is evolving in two significant ways. First, it is becoming more systemic and pervasive, extending across all layers of production, from upstream inputs and equipment to downstream applications, services, and frontier technologies. Biotechnology is squarely within this expanded scope, with visible gains in drug development, data processing, and advanced biomanufacturing. Second, these domestic dynamics are accelerating China's trade dominance, deepening foreign dependencies on Chinese supply chains, and fueling the global expansion of Chinese biotech firms.

The report also highlights areas where Chinese firms remain vulnerable, including biomedicine, where technological gaps persist despite substantial state support. China is adapting its policy playbook under tightening fiscal and macroeconomic constraints by recentralizing financial resources, consolidating government guidance funds, and pushing upgraded manufacturing across mature and emerging sectors. For the global biotech industry, the result is a more competitive, more self-reliant China that will increasingly shape markets for pharmaceuticals, biologics, and advanced diagnostics—while using policy tools to entrench its advantages and counter foreign diversification strategies.

Introduction

Biotechnology is a strategic pillar of China's long-term innovation agenda. The original Made in China 2025 plan identified biopharmaceuticals and high-performance medical devices as key targets. However, the new phase of industrial policy goes well beyond a list of strategic sectors. As the Rhodium Group report explains, Beijing is now mobilizing resources and coordinating policies across the entire economy to secure leadership in future industries—including gene editing, synthetic biology, personalized medicine, and AI-enabled drug discovery. The stakes are high, both for Chinese companies seeking to move up the value chain and for established biotech leaders in the United States, Europe, and Asia that have historically benefited from access to Chinese markets and supply chains.

This article examines what China's next-generation industrial policy means for biotechnology. Drawing on the evidence and analysis presented in the Rhodium Group report, it explores the scientific and technological advancement that is occurring, why it matters, how the industry is responding, and what the future may hold over the next decade and beyond.

Scientific Background

Biotechnology innovation is a complex, capital-intensive, and highly regulated field. Unlike software or consumer hardware, biotech companies must navigate lengthy drug-development timelines, biological validation, clinical trials, and reimbursement hurdles. This makes the sector particularly sensitive to industrial policy. Government support can shape not only research funding but also regulatory pathways, procurement, and access to capital.

In China, government-backed initiatives have accelerated the growth of the biotech sector. Advances in genomics, high-throughput screening, and biomanufacturing have positioned Chinese researchers to compete on the global stage. The country has invested heavily in biobanks, sequencing infrastructure, and research institutes that support both basic science and translational medicine. At the same time, Chinese companies are expanding into drug discovery and advanced therapeutic modalities, including cell and gene therapies.

The Rhodium Group assessment notes that Chinese industrial policy is now fused with the country's broader push for self-sufficiency and technological leadership. For biotech, this means concerted support for upstream inputs, such as serum-free media, bioreactor components, and specialized enzymes, as well as downstream capabilities like clinical-trial design and real-world data collection. The scientific basis of China's progress is real, but challenges remain in peer-reviewed advanced areas such as novel drug targets and platform technologies.

Research Findings

The Rhodium Group report, titled China's Next-Generation Industrial Policy, offers a data-driven analysis of the evolution and impact of Chinese industrial strategy. Key findings relevant to biotechnology include:

Policy expansion beyond MIC25: Industrial policy now spans the entire economy, including mature sectors and foundational supply-chain nodes. In biomedicine, this translates into continued state push despite sector-specific overcapacity in some traditional drug segments. Policymakers are not scaling back from mature sectors; instead, they are pushing companies toward higher-value products and improved production technologies, echoing strategies seen in other manufacturing industries.
Persistent vulnerabilities in biomedicine: The assessment confirms that Chinese firms have made substantial progress in reducing import dependence and building global positions in many sectors. However, significant gaps remain in biomedicine, where the technological gap has not yet been closed. This is consistent with earlier observations that biopharmaceutical R&D, especially for first-in-class drugs and complex biologics, still relies on foreign platforms and know-how.
Rising attention to services and drug development: Earlier industrial policy neglected services, but current frameworks are giving more attention to sectors such as software, data processing, and drug-development services. This shift is visible in the growth of Chinese contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs), which now serve global biotech companies while also accelerating domestic pipelines.
Demand creation as a new lever: Beyond R&D and production support, Chinese policymakers are now using public procurement and state-owned enterprises to drive adoption of new technologies. For biotech, this could mean preferential hospital procurement of domestically produced medical devices and drugs, as well as early adoption of digital-health and AI diagnostic tools.
Tighter centralization of resources: To manage financial constraints, Beijing is reducing wasteful local subsidies and consolidating funding vehicles. State guidance funds are being realigned to strategic priorities. Biotech startups, particularly those outside top-tier hubs, may find capital access more difficult, while national champions receive clearer allocations. This could accelerate the shift of private and public capital toward preferred areas such as AI-driven drug discovery and advanced biomanufacturing.

These findings indicate that China's next-generation industrial strategy is neither a retreat nor a simple continuation of MIC25. It is a more expansive, better-coordinated effort that uses both familiar and novel tools to achieve technological and market leadership.

Industry Impact

The implications for the global biotechnology industry are profound and multi-faceted.

For Chinese biotech companies, the state's renewed commitment translates into more funding, improved infrastructure, and clearer policy direction. Firms in areas like gene editing, in-vitro diagnostics, and vaccine development are likely to benefit from supportive procurement policies. However, increased state direction may also lead to redundancy, overinvestment, and a shift in incentives away from patient-centric innovation, as corporate decision-making becomes enmeshed with policy mandates.

For international biotech companies and investors, the report reveals a double-edged threat. On one hand, deeper Chinese participation in the global value chain can offer opportunities: access to Chinese patients in clinical trials, partnerships with CROs, and a shot at the country's growing healthcare market. On the other hand, China's accelerated trade dominance and import substitution reduce the market share of foreign drugs and devices. The report notes that Beijing is now using policy tools to deter foreign diversification, which could include strict IP regulations, local-data requirements, and supply-chain localization mandates. For multinational corporations, this means the old approach of using China as a production base and sales market is becoming less viable.

Supply-chain dependencies are shifting as well. Chinese companies already dominate key upstream segments such as active pharmaceutical ingredients (APIs) and some bioprocess consumables. As industrial policy pushes further, foreign companies may find themselves reliant on Chinese sources for these critical inputs—or faced with the costly task of building alternative supply chains. The report's observation that China's manufacturing surplus is growing and that foreign dependencies are deepening applies directly to biotechnology and pharmaceuticals.

The global healthcare system is likely to see both benefits and risks. China's scale and policy-driven investment could accelerate innovation and lower costs for some essential medicines and diagnostics. But the risk of supply-chain concentration is a serious concern for pandemic preparedness and geopolitical resilience. The report's evidence of China's accelerating trade dominance suggests that policymakers in other countries may consider more active industrial strategies themselves, potentially leading to a fragmentation of biotech research and development that slows down global medical progress.

Clinical & Regulatory Perspective

The Rhodium Group report is principally an industrial policy analysis, but its findings raise important considerations for clinical research and regulation.

On the scientific-evidence front, Chinese biotech has produced a growing number of drug candidates entering clinical trials. Some are generics or biosimilars; others are novel products, particularly in oncology and immunotherapy. However, the report's mention of biomedicine as a sector where China has not yet closed the technological gap signals caution. The strength of evidence supporting Chinese breakthroughs is still concentrated in a limited number of programs, and first-in-class innovation remains rare.

From a regulatory perspective, China has historically sought to harmonize its drug approval standards with international norms, but state involvement can create friction. The new industrial policy may accelerate the country's adoption of advanced theragnostic and companion diagnostics, while simultaneously using regulatory levers to protect domestic champions. Foreign companies already face requirements for local clinical trials and data exclusivity limitations. As China centralizes policy, these regulations are likely to become more clearly aligned with industrial objectives, potentially raising barriers for imported drugs.

Safety and efficacy concerns are not unique to China, but a policy landscape that pressures companies to move quickly may increase the risk of unrealistic timetables or preference for speed over rigor. International regulators and research partners should monitor whether China's push for self-sufficiency leads to lower evidentiary standards for landmark approvals. Ethical challenges, especially in the areas of human genomics, AI diagnostics, and gene editing, also demand careful scrutiny as policy-driven funding expands.

Future Outlook

Looking ahead to the next 5–15 years, the report suggests that China's biotech industrial policy will continue to intensify and globalize.

Artificial intelligence in drug discovery will likely be a key battlefield. The report highlights AI as a central pillar of China's current industrial push. AI-enabled platforms may allow Chinese firms to leapfrog certain stages of drug development, though whether they can reach genuinely novel targets remains an open question. If state support creates a thriving ecosystem of AI-first biotech startups, the impact on global drug discovery could be staggering.

Gene editing and synthetic biology are also likely to see heavy state investment, given their strategic significance. The leadership's willingness to fund 'future industries' could make China a world leader in low-cost DNA synthesis and engineered cell therapies. Yet foundational patents and proprietary enzyme engineering still mostly belong to American and European firms. This tension may persist for years.

Precision medicine and biobanking will benefit from China's enormous patient population and data integration, but will also raise concerns about scientific ethics and data governance. The state's control over data may facilitate research speed but could also limit international collaboration.

In biomanufacturing, Chinese firms may increasingly provide CDMO services that are cost-competitive but also leverage state support. Global pharma will have to decide whether to link up with these Chinese platforms or invest in parallel capacities elsewhere. The report's finding that China's industrial policy aims to cement its role as a central node in value chains suggests that it intends to become the 'pharmacy of the world' for a much broader range of products.

The investment climate will remain turbulent. State guidance and recentralized financial systems can shift money quickly into promising but unproven technologies, creating bubbles. Meanwhile, foreign venture capital and multinational R&D organizations may slowly exit China due to regulatory unpredictability, only to be replaced by state-affiliated capital like the National Integrated Circuit Fund’s biotech equivalents. The report did not provide a detailed breakdown on biotech, but its general observations about centralization and resource reallocation point in that direction.

Finally, geopolitics will remain the wild card. The accelerating trade dominance and China’s new tools to deter foreign diversification may lead to reciprocal measures in the West. For the biotech sector, where scientific exchange and data sharing have traditionally been global, this could become more fragmented. Future medicine depends on international collaboration, and any policy that erodes that foundation—wherever it originates—demands attention.

Conclusion

China's next-generation industrial policy marks a departure from the earlier, more contained approach of Made in China 2025. It is now a comprehensive, deeply integrated strategy to elevate Chinese industry across the board, including the many segments of biotechnology. The Rhodium Group report, on which this analysis is based, provides a clear evidence base: China is doubling down, not retreating. For the life sciences community, this brings both opportunities and risks. Chinese firms and researchers will continue to gain capabilities, competition will heighten, and supply-chain interconnections will persist—but the era of easy access to Chinese markets is likely fading. The global response will need to be based on facts, not hype, and must acknowledge that prior warnings about Chinese industrial policy have more often been accurate than alarmist. For biotech companies, policymakers, and healthcare leaders, the strategic choices ahead will shape not just corporate profits, but the future of medicine and human health in a rapidly changing world.